• Yue-Han Guo, Le Zhou, Zi-Ang Cui, Jian Wang, Lei Zhang, Ting Xu, Yi-Dan Xie, and Hui Chen.
• Department of Pharmacy, Wuhan Mental Health Center, Wuhan, Hubei, China.
• Medicine (Baltimore). 2023 Nov 10; 102 (45): e35871e35871.

ObjectiveTo systematically assess the efficacy and safety of agomelatine in the treatment of patients with depressive disorder.MethodsRandomized controlled trials (RCTs) related to agomelatine in the treatment of patients with depressive disorder published in PubMed, Web of Science, CNKI, VIP, and Wangfang were retrieved. Extracted data on the efficacy and safety of agomelatine and placebo in the treatment of depressive disorder, and the collected data were processed by RevMan5.4 software.ResultsA total of 10 RCTs were included. Meta-analysis showed that the HAMD-17 total scores of agomelatine group were statistically different from those of placebo group (odds ratio [OR]: 2.04, 95% confidence intervals [CIs]: 1.71-2.43, P < .001). High heterogeneity was found between agomelatine groups and placebo groups (P < .0001, and I2 = 78%), so a subgroup analysis was further performed, and the heterogeneity became insignificant (P = .33, and I2 = 14%) after excluding the studies, of which course of treatment was 24 weeks or the sample size was relatively small. The adverse events between agomelatine and placebo groups were not statistically significant (OR: 1.15, 95% CIs: 0.69-1.92; P = .05).ConclusionAgomelatine was superior comparable to placebo in the treatment of patients with depressive disorder, and has fewer adverse events.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

15 keywords...

hide…